期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 57, 期 10, 页码 1528-1538出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2005.04.006
关键词
bacterial genomics; target validation; compound libraries; lead identification; new class antibacterials
Resistance to marketed antibiotics continues to increase. During the last 10 years some 200 bacterial genome sequences have become available, giving rise to expectations that genomics would provide a plethora of novel targets and hence a flood of new therapeutic agents. Contrary to some predictions the genomic effort has yet to yield a substantial number of novel class agents in clinical development. What are the reasons for the differences between expectations and reality? This article reviews what has been achieved in the exploitation of bacterial genomes for the discovery of novel antibacterials. (c) 2005 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据